Alpha-L-fucosidase 1 (FUCA1) (FUCA1)

Alpha-L-fucosidase 1 (FUCA1) is a lysosomal enzyme that catalyzes the hydrolysis of terminal alpha-L-fucose residues from various glycoconjugates, including glycoproteins and glycolipids (UniProt P04066). This enzymatic process is vital for the normal turnover of fucose-containing molecules within the lysosome. A deficiency in FUCA1 activity leads to fucosidosis, a severe lysosomal storage disorder characterized by the accumulation of fucose-containing compounds in tissues, leading to neurodegeneration and growth retardation (NIH GARD). In clinical oncology, elevated serum levels of alpha-L-fucosidase are utilized as a diagnostic and prognostic biomarker for hepatocellular carcinoma, often showing higher sensitivity than alpha-fetoprotein in early-stage detection (PMID: 30264318). Pharmacological interest in FUCA1 involves the development of iminosugar-based inhibitors, such as deoxyfuconojirimycin, which are used to study glycan processing and potential anti-metastatic effects in cancer research (PubChem CID 123954). Therapeutic strategies under investigation include enzyme replacement therapy and gene therapy to restore enzymatic function in affected individuals.

Other names

Alpha-L-fucoside fucohydrolaseTissue alpha-L-fucosidaseAFUFUCAAlpha-L-fucosidase

Competitive inhibition of the enzyme's active site to prevent the cleavage of terminal L-fucose residues from glycoconjugates.